Century Therapeutics reported a FY 2025 net loss of USD 9.58 million, compared with a net loss of USD 126.57 million a year earlier. Collaboration revenue in FY 2025 was USD 109.16 million, while R&D expenses fell 11% to USD 95.67 million due to lower personnel and manufacturing costs, partly offset by higher research and laboratory costs. G&A expenses decreased 28% to USD 24 million. Cash, cash equivalents and marketable securities were USD 117.1 million as of Dec. 31, 2025, down 47% from a year earlier, and the company said its cash runway extends into Q1 2029 after an oversubscribed USD 135 million private placement in January 2026. Chief Executive Officer Brent Pfeiffenberger said Century expects to submit an IND for CNTY-813 in Q4 2026 and anticipates initial clinical data in 2H 2027, while CNTY-308 remains on track to enter the clinic in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120800PRIMZONEFULLFEED9670353) on March 12, 2026, and is solely responsible for the information contained therein.